BHVN – biohaven pharmaceutical holding company ltd. common shares (US:NASDAQ)

News

Biohaven (BHVN) had its price target lowered by HC Wainwright from $11.00 to $10.00. They now have a "neutral" rating on the stock.
Biohaven (BHVN) had its "outperform" rating reaffirmed by Leerink Partners.
Biohaven (BHVN) had its price target raised by Royal Bank Of Canada from $22.00 to $23.00. They now have an "outperform" rating on the stock.
Biohaven Non-GAAP EPS of -$0.90 beats by $0.06 [Seeking Alpha]
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com